{
  "run_name": "data/proposed_annotations",
  "timestamp": "2026-01-11_14-39-17",
  "benchmark_variants": [
    "rs9923231",
    "rs1057910",
    "rs2108622",
    "rs887829",
    "CYP2B6*1, CYP2B6*9",
    "rs3745274",
    "rs2472677",
    "rs1045642",
    "rs28399499",
    "rs4803419",
    "CYP2C19*1, CYP2C19*2, CYP2C19*17",
    "HLA-B*58:01",
    "HLA-DRB1*03:01",
    "HLA-C*03:02",
    "HLA-A*33:03",
    "rs1594",
    "HLA-B*67:01",
    "HLA-B*78:01",
    "HLA-B*51:02",
    "HLA-B*56:06",
    "HLA-B*39:01",
    "HLA-C*05:09",
    "HLA-B*15:32",
    "HLA-C*05:01",
    "HLA-B*51:01",
    "HLA-B*15:35",
    "HLA-B*15:12",
    "HLA-DRB1*08:01",
    "HLA-B*39:10",
    "HLA-B*38:02",
    "HLA-B*38:01",
    "HLA-DRB1*04:04",
    "HLA-B*56:01",
    "HLA-B*35:05",
    "HLA-DRB1*01:02",
    "HLA-B*39:09",
    "HLA-B*15:01",
    "HLA-B*15:27",
    "HLA-B*35:10",
    "HLA-C*04:06",
    "HLA-B*57:01",
    "HLA-C*04:07",
    "HLA-B*55:02",
    "HLA-DRB1*01:03",
    "HLA-B*55:01",
    "HLA-B*13:02",
    "HLA-B*15:25",
    "HLA-B*39:06",
    "HLA-C*04:03",
    "HLA-B*54:01",
    "HLA-DRB1*01:01",
    "HLA-B*52:01",
    "HLA-DRB1*10:01",
    "HLA-C*04:01",
    "HLA-B*39:05",
    "HLA-C*18:01",
    "HLA-B*15:24",
    "UGT1A1*1, UGT1A1*6, UGT1A1*28",
    "UGT1A1*1, UGT1A1*28",
    "UGT1A1*1, UGT1A1*6",
    "rs1142345",
    "rs116855232",
    "rs4149056",
    "rs2306283",
    "CYP2C19 intermediate metabolizer",
    "CYP2D6 poor metabolizer",
    "rs6311",
    "rs1801265",
    "rs1695",
    "rs11280056",
    "rs45445694",
    "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
    "rs2740574",
    "rs9282564",
    "rs2273697",
    "rs776746",
    "rs4244285",
    "CYP2D6*1, CYP2D6*3, CYP2D6*4",
    "CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6",
    "CYP2D6*1, CYP2D6*10, CYP2D6*41",
    "rs2043211",
    "rs4612666",
    "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
    "CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31",
    "CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33",
    "HLA-DQA1*02:01",
    "HLA-DQB1*02:02",
    "HLA-DRB1*07:01",
    "rs9958628",
    "HLA-B*15:02",
    "HLA-A*31:01",
    "rs56038477",
    "rs1801160",
    "rs2297595",
    "CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41",
    "NUDT15*3",
    "HLA-B*13:01",
    "CYP2C9*1, CYP2C9*2, CYP2C9*3",
    "rs2231142",
    "CYP4F2*1, CYP4F2*3",
    "CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8",
    "rs1800566",
    "CYP2B6*1, CYP2B6*6",
    "rs1800460",
    "rs1800462",
    "HLA-B*35:01",
    "rs2054675",
    "rs3786547"
  ],
  "proposed_variants": [
    "VKORC1 \u2212 1639G > A, CYP2C9*3",
    "CYP4F2 rs2108622",
    "UGT1A1 rs887829",
    "VKORC1 \u2212 1639G > A",
    "CYP2C9*3",
    "CYP2B6 983TC/CC",
    "CYP2B6 15582CT/TT",
    "ABCB1 3435TT",
    "CYP2B6 516GT/TT",
    "NR1I2 63396TT",
    "Dose",
    "CYP2C19*2, CYP2C19*17",
    "CYP2C19*3",
    "CYP2C19*17",
    "CYP2C19*2 (rs4244285)",
    "CYP2C19*17 (rs12248560)",
    "CYP2C19*2",
    "HLA-B*5801",
    "HLA-A*3303",
    "Cw*0302",
    "DRB1*0301",
    "HLA-C*04:01",
    "HLA-C*05:01",
    "HLA-C*18:01",
    "HLA-B*15:01",
    "HLA-DRB1*01:01",
    "HLA-DRB1*04:04",
    "HLA-C*05:01, HLA-C*18:01",
    "UGT1A1*6",
    "rs116855232",
    "NUDT15 rs116855232 (R139C)",
    "rs4149056 c.521T>C or *1b/*15",
    "SLCO1B1 c.521T>C, SLCO1B1*1b/*15",
    "SLCO1B1 c.521T>C",
    "CYP2C19 IM, CYP2C19 NM, CYP2C19 RM, CYP2C19 UM",
    "CYP2D6 IM, CYP2D6 NM",
    "HTR2A A/A, HTR2A A/G",
    "CYP2C19 IM, NM, RM",
    "CYP2D6 IM, PM",
    "HTR2A A/G, A/A",
    "CYP2C19 IM",
    "CYP2D6 IM",
    "HTR2A A/A and A/G",
    "rs1801265",
    "rs1695",
    "rs11280056",
    "rs45445694",
    "DPYD rs1801265 C at risk",
    "GSTP1 rs1695 G allele",
    "TYMS deletion genotype rs11280056",
    "TYMS 5'UTR 3R genotype rs45445694",
    "MTHFR rs1801131 C allele",
    "CYP2D6 poor metabolizers, CYP2D6 intermediate metabolizers, CYP2D6 normal metabolizers, CYP2D6 ultrarapid metabolizers",
    "CYP2D6 poor metabolizer",
    "CYP2D6 intermediate metabolizer",
    "CYP2D6 normal/ultrarapid metabolizer",
    "CYP2D6 *4/*4",
    "ABCB1_rs9282564",
    "ABCC2_rs2273697",
    "CYP3A5_rs776746",
    "CYP2B6_rs3745274",
    "CYP2C19_rs4244285",
    "CYP3A5 *3/*3",
    "ABCB1 rs9282564",
    "ABCC2 rs2273697",
    "CYP2B6 rs3745274",
    "CYP2C19 rs4244285",
    "CYP3A5*3",
    "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
    "CYP2D6 *4",
    "CYP2D6 *3, *4, *6, *10, *41",
    "rs2043211",
    "rs4612666",
    "CARD8 rs2043211",
    "NLRP3 rs4612666",
    "CARD8 (rs2043211)",
    "NLRP3 (rs4612666)",
    "CYP2C19 LOF allele",
    "CYP2C19*1/*1, CYP2C19*1/*17, CYP2C19*17/*17 (extensive metabolizers)",
    "CYP2C19*1/*1",
    "CYP3A4*11",
    "CYP3A4*18",
    "CYP3A4*33",
    "CYP3A4*2",
    "CYP3A4*3",
    "CYP3A4*24",
    "CYP3A4*30",
    "CYP3A4*17",
    "CYP3A4*1",
    "CYP3A4*1G",
    "HLA-DQB1*02:02, HLA-DRB1*07:01, HLA-DQA1*02:01",
    "rs9958628",
    "HLA-DQB1*02:02",
    "HLA-DRB1*07:01",
    "HLA-DQA1*02:01",
    "ARHGAP28 rs9958628",
    "UGT1A1*6 or *28 (+/+), UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
    "UGT1A1*6 or *28 (+/+), UGT1A1*6 or *28 (-/-), UGT1A1*6 or *28 (+/-)",
    "UGT1A1 polymorphism",
    "UGT1A1*6 or *28 (+/+)",
    "HLA-A*31:01",
    "HLA-B*15:02",
    "rs1061235",
    "HLA-A\u26053101",
    "HLA-A*3101",
    "c.1679T>G (DPYD*13, rs55886062)",
    "c.1905+1G>A (DPYD*2A, rs3918290)",
    "c.2846A>T (rs67376798)",
    "c.1679T>G (DPYD*13)",
    "c.1905+1G>A (DPYD*2A)",
    "c.2846A>T",
    "HLA-B*5701, Hsp70-Hom M493T",
    "HLA-B*5701",
    "CYP2D6*1, CYP2D6*10, CYP2D6*2, CYP2D6*5, CYP2D6*3, CYP2D6*4, CYP2D6*41",
    "CYP2D6 *1/*1",
    "CYP2D6 *10/*10",
    "CYP2D6 *41/*41",
    "CYP2D6 *10/*41",
    "CYP2D6*1/*1",
    "CYP2D6*10",
    "CYP2D6*10/*10",
    "CYP2D6*1/*41",
    "*3/*3",
    "NUDT15 *3/*3",
    "HLA-A*11:01",
    "HLA-B*13:01",
    "HLA-B*38:02",
    "HLA-C*08:01",
    "HLA-A*68:01",
    "HLA-B*39:01",
    "c.521C/C",
    "c.521T>C",
    "rs2231142",
    "rs1057910, rs1799853",
    "SLCO1B1 c.521C/C",
    "ABCG2 c.421C>A",
    "SLCO1B1 c.521T/T",
    "CYP2C9*2",
    "VKORC1-1639A",
    "CYP4F2*3",
    "NQO1*2",
    "CYP2C9*2, CYP2C9*3, CYP2C9*8",
    "VKORC1-1639G>A",
    "VKORC1-1639 G>A",
    "388A>G (rs2306283)",
    "521T>C (rs4149056)",
    "388A>G",
    "521T>C",
    "388A/521T haplotype",
    "388A>G, 521T>C",
    "CYP2B6-G516T",
    "CYP2B6-G516T (TT)",
    "CYP2B6-G516T (GT)",
    "CYP2B6-G516T (GG)",
    "CYP2B6*6 (rs3745274, rs2279343)",
    "CYP2B6*1/*6",
    "CYP2B6*6",
    "rs1800462",
    "rs1800460",
    "rs1142345",
    "CYP2B6 516G\u2192T",
    "HLA-Cw*04",
    "HLA-B*35",
    "HLA-DRB*01",
    "HLA-DRB1*01"
  ],
  "article_variant_breakdown": [
    {
      "title": "The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients",
      "pmcid": "PMC5508045",
      "benchmark_variants": [
        "rs9923231",
        "rs1057910",
        "rs2108622",
        "rs887829"
      ],
      "proposed_variants": [
        "VKORC1 \u2212 1639G > A, CYP2C9*3",
        "CYP4F2 rs2108622",
        "UGT1A1 rs887829",
        "VKORC1 \u2212 1639G > A",
        "CYP2C9*3",
        "CYP4F2 rs2108622",
        "UGT1A1 rs887829",
        "VKORC1 \u2212 1639G > A",
        "CYP2C9*3",
        "CYP4F2 rs2108622",
        "UGT1A1 rs887829"
      ]
    },
    {
      "title": "Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Nai\u0308ve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study",
      "pmcid": "PMC4916189",
      "benchmark_variants": [
        "CYP2B6*1, CYP2B6*9",
        "rs3745274",
        "rs2472677",
        "rs3745274",
        "rs1045642",
        "rs28399499",
        "rs4803419"
      ],
      "proposed_variants": [
        "CYP2B6 983TC/CC",
        "CYP2B6 15582CT/TT",
        "ABCB1 3435TT",
        "CYP2B6 516GT/TT",
        "NR1I2 63396TT",
        "CYP2B6 983TC/CC",
        "CYP2B6 15582CT/TT",
        "ABCB1 3435TT",
        "Dose",
        "CYP2B6 516GT/TT",
        "CYP2B6 983TC/CC",
        "CYP2B6 15582CT/TT",
        "ABCB1 3435TT"
      ]
    },
    {
      "title": "The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease",
      "pmcid": "PMC12036300",
      "benchmark_variants": [
        "CYP2C19*1, CYP2C19*2, CYP2C19*17",
        "CYP2C19*1, CYP2C19*2, CYP2C19*17"
      ],
      "proposed_variants": [
        "CYP2C19*2, CYP2C19*17",
        "CYP2C19*3",
        "CYP2C19*17",
        "CYP2C19*2 (rs4244285)",
        "CYP2C19*17 (rs12248560)",
        "CYP2C19*2",
        "CYP2C19*3",
        "CYP2C19*17"
      ]
    },
    {
      "title": "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol",
      "pmcid": "PMC554812",
      "benchmark_variants": [
        "HLA-B*58:01",
        "HLA-DRB1*03:01",
        "HLA-C*03:02",
        "HLA-A*33:03",
        "rs1594"
      ],
      "proposed_variants": [
        "HLA-B*5801",
        "HLA-B*5801",
        "HLA-B*5801",
        "HLA-A*3303",
        "Cw*0302",
        "DRB1*0301"
      ]
    },
    {
      "title": "Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles",
      "pmcid": "PMC5561238",
      "benchmark_variants": [
        "HLA-B*67:01",
        "HLA-B*78:01",
        "HLA-B*51:02",
        "HLA-B*56:06",
        "HLA-B*39:01",
        "HLA-C*05:09",
        "HLA-B*15:32",
        "HLA-C*05:01",
        "HLA-B*51:01",
        "HLA-B*15:35",
        "HLA-B*15:12",
        "HLA-DRB1*08:01",
        "HLA-B*39:10",
        "HLA-B*38:02",
        "HLA-B*38:01",
        "HLA-DRB1*04:04",
        "HLA-B*56:01",
        "HLA-B*35:05",
        "HLA-DRB1*01:02",
        "HLA-B*39:09",
        "HLA-B*15:01",
        "HLA-B*15:27",
        "HLA-B*35:10",
        "HLA-C*04:06",
        "HLA-B*57:01",
        "HLA-C*04:07",
        "HLA-B*55:02",
        "HLA-DRB1*01:03",
        "HLA-B*55:01",
        "HLA-B*13:02",
        "HLA-B*15:25",
        "HLA-B*39:06",
        "HLA-C*04:03",
        "HLA-B*54:01",
        "HLA-DRB1*01:01",
        "HLA-B*52:01",
        "HLA-DRB1*10:01",
        "HLA-C*04:01",
        "HLA-B*39:05",
        "HLA-C*18:01",
        "HLA-B*15:24",
        "rs28399499",
        "rs3745274"
      ],
      "proposed_variants": [
        "HLA-C*04:01",
        "HLA-C*05:01",
        "HLA-C*18:01",
        "HLA-B*15:01",
        "HLA-DRB1*01:01",
        "HLA-C*04:01",
        "HLA-C*05:01",
        "HLA-B*15:01",
        "HLA-DRB1*01:01",
        "HLA-DRB1*04:04",
        "HLA-C*04:01",
        "HLA-B*15:01",
        "HLA-DRB1*01:01",
        "HLA-C*05:01, HLA-C*18:01"
      ]
    },
    {
      "title": "Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer",
      "pmcid": "PMC10946077",
      "benchmark_variants": [
        "UGT1A1*1, UGT1A1*6, UGT1A1*28",
        "UGT1A1*1, UGT1A1*28",
        "UGT1A1*1, UGT1A1*6"
      ],
      "proposed_variants": [
        "UGT1A1*6",
        "UGT1A1*6",
        "UGT1A1*6",
        "UGT1A1*6",
        "UGT1A1*6"
      ]
    },
    {
      "title": "NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis",
      "pmcid": "PMC6465603",
      "benchmark_variants": [
        "rs1142345",
        "rs116855232"
      ],
      "proposed_variants": [
        "rs116855232",
        "rs116855232",
        "NUDT15 rs116855232 (R139C)"
      ]
    },
    {
      "title": "Impacts of Pharmacokinetic Gene Polymorphisms on Steady\u2010State Plasma Concentrations of Simvastatin in Thai Population",
      "pmcid": "PMC12038368",
      "benchmark_variants": [
        "rs4149056",
        "rs2306283"
      ],
      "proposed_variants": [
        "rs4149056 c.521T>C or *1b/*15",
        "SLCO1B1 c.521T>C, SLCO1B1*1b/*15",
        "SLCO1B1 c.521T>C"
      ]
    },
    {
      "title": "Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study",
      "pmcid": "PMC10880264",
      "benchmark_variants": [
        "CYP2C19 intermediate metabolizer",
        "CYP2D6 poor metabolizer",
        "CYP2C19 intermediate metabolizer",
        "rs6311"
      ],
      "proposed_variants": [
        "CYP2C19 IM, CYP2C19 NM, CYP2C19 RM, CYP2C19 UM",
        "CYP2D6 IM, CYP2D6 NM",
        "HTR2A A/A, HTR2A A/G",
        "CYP2C19 IM, NM, RM",
        "CYP2D6 IM, PM",
        "HTR2A A/G, A/A",
        "CYP2C19 IM",
        "CYP2D6 IM",
        "HTR2A A/A and A/G"
      ]
    },
    {
      "title": "Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer",
      "pmcid": "PMC12331468",
      "benchmark_variants": [
        "rs1801265",
        "rs1695",
        "rs11280056",
        "rs45445694",
        "rs1695"
      ],
      "proposed_variants": [
        "rs1801265",
        "rs1695",
        "rs11280056",
        "rs45445694",
        "rs1695",
        "rs1801265",
        "rs11280056",
        "rs45445694",
        "DPYD rs1801265 C at risk",
        "GSTP1 rs1695 G allele",
        "TYMS deletion genotype rs11280056",
        "TYMS 5'UTR 3R genotype rs45445694",
        "MTHFR rs1801131 C allele"
      ]
    },
    {
      "title": "CYP2D6 genotype and adverse events to risperidone in children and adolescents",
      "pmcid": "PMC6435416",
      "benchmark_variants": [
        "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41"
      ],
      "proposed_variants": [
        "CYP2D6 poor metabolizers, CYP2D6 intermediate metabolizers, CYP2D6 normal metabolizers, CYP2D6 ultrarapid metabolizers",
        "CYP2D6 poor metabolizer",
        "CYP2D6 intermediate metabolizer",
        "CYP2D6 normal/ultrarapid metabolizer",
        "CYP2D6 *4/*4"
      ]
    },
    {
      "title": "Pharmacogenetics association with long-term clinical evolution in a kidney transplant patients cohort",
      "pmcid": "PMC12319246",
      "benchmark_variants": [
        "rs2740574",
        "rs3745274",
        "rs2306283",
        "rs9282564",
        "rs2273697",
        "rs776746",
        "rs4149056",
        "rs4244285"
      ],
      "proposed_variants": [
        "ABCB1_rs9282564",
        "ABCC2_rs2273697",
        "CYP3A5_rs776746",
        "CYP2B6_rs3745274",
        "CYP2C19_rs4244285",
        "CYP3A5 *3/*3",
        "ABCB1 rs9282564",
        "ABCC2 rs2273697",
        "CYP2B6 rs3745274",
        "CYP2C19 rs4244285",
        "CYP3A5*3",
        "CYP2C19*2",
        "ABCB1 rs9282564"
      ]
    },
    {
      "title": "CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8",
      "pmcid": "PMC3548984",
      "benchmark_variants": [
        "CYP2D6*1, CYP2D6*3, CYP2D6*4",
        "CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6",
        "CYP2D6*1, CYP2D6*10, CYP2D6*41"
      ],
      "proposed_variants": [
        "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
        "CYP2D6 *4",
        "CYP2D6 *3, *4, *6, *10, *41"
      ]
    },
    {
      "title": "Effect of NLRP3 inflammasome genes polymorphism on disease susceptibility and response to TNF-\u03b1 inhibitors in Iraqi patients with rheumatoid arthritis",
      "pmcid": "PMC10275785",
      "benchmark_variants": [
        "rs2043211",
        "rs4612666"
      ],
      "proposed_variants": [
        "rs2043211",
        "rs4612666",
        "CARD8 rs2043211",
        "NLRP3 rs4612666",
        "CARD8 (rs2043211)",
        "NLRP3 (rs4612666)"
      ]
    },
    {
      "title": "Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical Trial",
      "pmcid": "PMC11971672",
      "benchmark_variants": [
        "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17"
      ],
      "proposed_variants": [
        "CYP2C19 LOF allele",
        "CYP2C19*1/*1, CYP2C19*1/*17, CYP2C19*17/*17 (extensive metabolizers)",
        "CYP2C19 LOF allele",
        "CYP2C19 LOF allele",
        "CYP2C19*1/*1"
      ]
    },
    {
      "title": "The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population",
      "pmcid": "PMC11430164",
      "benchmark_variants": [
        "CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31",
        "CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33"
      ],
      "proposed_variants": [
        "CYP3A4*11",
        "CYP3A4*18",
        "CYP3A4*33",
        "CYP3A4*2",
        "CYP3A4*3",
        "CYP3A4*24",
        "CYP3A4*30",
        "CYP3A4*17",
        "CYP3A4*1",
        "CYP3A4*2",
        "CYP3A4*11",
        "CYP3A4*18",
        "CYP3A4*30",
        "CYP3A4*24",
        "CYP3A4*1G"
      ]
    },
    {
      "title": "Class II HLA Variants Associate with Risk of Pegaspargase Hypersensitivity",
      "pmcid": "PMC8790808",
      "benchmark_variants": [
        "HLA-DQA1*02:01",
        "HLA-DQB1*02:02",
        "HLA-DRB1*07:01",
        "rs9958628"
      ],
      "proposed_variants": [
        "HLA-DQB1*02:02, HLA-DRB1*07:01, HLA-DQA1*02:01",
        "rs9958628",
        "HLA-DQB1*02:02",
        "HLA-DRB1*07:01",
        "HLA-DQA1*02:01",
        "ARHGAP28 rs9958628",
        "HLA-DQB1*02:02",
        "HLA-DRB1*07:01",
        "HLA-DQA1*02:01",
        "rs9958628"
      ]
    },
    {
      "title": "Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin",
      "pmcid": "PMC11062152",
      "benchmark_variants": [
        "UGT1A1*1, UGT1A1*6, UGT1A1*28",
        "UGT1A1*1, UGT1A1*6, UGT1A1*28"
      ],
      "proposed_variants": [
        "UGT1A1*6 or *28 (+/+), UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
        "UGT1A1*6 or *28 (+/+), UGT1A1*6 or *28 (-/-), UGT1A1*6 or *28 (+/-)",
        "UGT1A1 polymorphism",
        "UGT1A1*6 or *28 (+/+)"
      ]
    },
    {
      "title": "HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children",
      "pmcid": "PMC3839910",
      "benchmark_variants": [
        "HLA-B*15:02",
        "HLA-B*15:02",
        "HLA-A*31:01",
        "HLA-A*31:01",
        "HLA-A*31:01",
        "HLA-B*15:02"
      ],
      "proposed_variants": [
        "HLA-A*31:01",
        "HLA-B*15:02",
        "rs1061235",
        "HLA-B*15:02",
        "HLA-A*31:01",
        "HLA-A*31:01",
        "HLA-B*15:02"
      ]
    },
    {
      "title": "HLA-A\u26053101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans",
      "pmcid": "PMC3113609",
      "benchmark_variants": [
        "HLA-A*31:01",
        "HLA-A*31:01",
        "HLA-A*31:01"
      ],
      "proposed_variants": [
        "HLA-A\u26053101",
        "HLA-A\u26053101",
        "HLA-A*3101"
      ]
    },
    {
      "title": "Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity",
      "pmcid": "PMC10786722",
      "benchmark_variants": [
        "rs56038477",
        "rs1801160",
        "rs2297595"
      ],
      "proposed_variants": [
        "c.1679T>G (DPYD*13, rs55886062)",
        "c.1905+1G>A (DPYD*2A, rs3918290)",
        "c.2846A>T (rs67376798)",
        "c.1679T>G (DPYD*13)",
        "c.1905+1G>A (DPYD*2A)",
        "c.2846A>T",
        "c.1905+1G>A (DPYD*2A)"
      ]
    },
    {
      "title": "Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant",
      "pmcid": "PMC384715",
      "benchmark_variants": [
        "HLA-B*57:01"
      ],
      "proposed_variants": [
        "HLA-B*5701, Hsp70-Hom M493T",
        "HLA-B*5701, Hsp70-Hom M493T",
        "HLA-B*5701, Hsp70-Hom M493T",
        "HLA-B*5701"
      ]
    },
    {
      "title": "CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer",
      "pmcid": "PMC3584248",
      "benchmark_variants": [
        "CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41",
        "CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41"
      ],
      "proposed_variants": [
        "CYP2D6*1, CYP2D6*10, CYP2D6*2, CYP2D6*5, CYP2D6*3, CYP2D6*4, CYP2D6*41",
        "CYP2D6 *1/*1",
        "CYP2D6 *10/*10",
        "CYP2D6 *41/*41",
        "CYP2D6 *10/*41",
        "CYP2D6*1/*1",
        "CYP2D6*10",
        "CYP2D6*10/*10",
        "CYP2D6*1/*41"
      ]
    },
    {
      "title": "Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency",
      "pmcid": "PMC12035587",
      "benchmark_variants": [
        "NUDT15*3"
      ],
      "proposed_variants": [
        "*3/*3",
        "NUDT15 *3/*3",
        "NUDT15 *3/*3"
      ]
    },
    {
      "title": "Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole-Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis",
      "pmcid": "PMC10993165",
      "benchmark_variants": [
        "HLA-B*15:02",
        "HLA-B*13:01",
        "HLA-B*38:02"
      ],
      "proposed_variants": [
        "HLA-A*11:01",
        "HLA-B*13:01",
        "HLA-B*15:02",
        "HLA-B*38:02",
        "HLA-C*08:01",
        "HLA-A*68:01",
        "HLA-B*39:01",
        "HLA-A*11:01",
        "HLA-B*13:01",
        "HLA-B*15:02",
        "HLA-B*38:02",
        "HLA-C*08:01",
        "HLA-A*68:01",
        "HLA-B*39:01",
        "HLA-A*11:01",
        "HLA-B*13:01",
        "HLA-B*15:02",
        "HLA-B*38:02",
        "HLA-C*08:01"
      ]
    },
    {
      "title": "Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants",
      "pmcid": "PMC10399933",
      "benchmark_variants": [
        "CYP2C9*1, CYP2C9*2, CYP2C9*3",
        "rs4149056",
        "rs2231142",
        "rs4149056",
        "rs4149056"
      ],
      "proposed_variants": [
        "c.521C/C",
        "c.521T>C",
        "c.521T>C",
        "rs2231142",
        "rs1057910, rs1799853",
        "SLCO1B1 c.521C/C",
        "SLCO1B1 c.521T>C",
        "ABCG2 c.421C>A",
        "SLCO1B1 c.521C/C",
        "SLCO1B1 c.521T>C",
        "SLCO1B1 c.521T/T",
        "ABCG2 c.421C>A"
      ]
    },
    {
      "title": "A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics",
      "pmcid": "PMC4706412",
      "benchmark_variants": [
        "CYP4F2*1, CYP4F2*3",
        "CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8",
        "rs9923231",
        "rs1800566"
      ],
      "proposed_variants": [
        "CYP2C9*2",
        "CYP2C9*3",
        "VKORC1-1639A",
        "CYP4F2*3",
        "NQO1*2",
        "CYP2C9*2, CYP2C9*3, CYP2C9*8",
        "VKORC1-1639G>A",
        "CYP2C9*2",
        "CYP2C9*3",
        "VKORC1-1639 G>A"
      ]
    },
    {
      "title": "Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia",
      "pmcid": "PMC6714829",
      "benchmark_variants": [
        "rs4149056",
        "rs2306283"
      ],
      "proposed_variants": [
        "388A>G (rs2306283)",
        "521T>C (rs4149056)",
        "388A>G",
        "521T>C",
        "388A/521T haplotype",
        "388A>G, 521T>C",
        "388A>G, 521T>C"
      ]
    },
    {
      "title": "Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults",
      "pmcid": "PMC2859392",
      "benchmark_variants": [
        "rs3745274",
        "rs3745274"
      ],
      "proposed_variants": [
        "CYP2B6-G516T",
        "CYP2B6-G516T",
        "CYP2B6-G516T",
        "CYP2B6-G516T (TT)",
        "CYP2B6-G516T (GT)",
        "CYP2B6-G516T (GG)"
      ]
    },
    {
      "title": "Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis",
      "pmcid": "PMC11603346",
      "benchmark_variants": [
        "CYP2B6*1, CYP2B6*6",
        "CYP2B6*1, CYP2B6*6"
      ],
      "proposed_variants": [
        "CYP2B6*6 (rs3745274, rs2279343)",
        "CYP2B6*1/*6",
        "CYP2B6*6 (rs3745274, rs2279343)",
        "CYP2B6*1/*6",
        "CYP2B6*6"
      ]
    },
    {
      "title": "Susceptibility to thiopurine toxicity by TPMT and NUDT15 variants in Colombian children with acute lymphoblastic leukemia",
      "pmcid": "PMC8973308",
      "benchmark_variants": [
        "rs116855232",
        "rs1800460",
        "rs1800462"
      ],
      "proposed_variants": [
        "rs1800462",
        "rs1800460",
        "rs1142345",
        "rs116855232",
        "rs1800462",
        "rs1800460",
        "rs1142345",
        "rs1800462",
        "rs1800460",
        "rs1142345",
        "rs116855232"
      ]
    },
    {
      "title": "Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent",
      "pmcid": "PMC3387531",
      "benchmark_variants": [
        "HLA-B*35:01",
        "HLA-DRB1*01:01",
        "HLA-C*04:01",
        "rs3745274",
        "rs2054675",
        "rs3786547"
      ],
      "proposed_variants": [
        "CYP2B6 516G\u2192T",
        "HLA-Cw*04",
        "HLA-B*35",
        "HLA-DRB*01",
        "CYP2B6 516G\u2192T",
        "CYP2B6 516G\u2192T",
        "HLA-Cw*04",
        "HLA-B*35",
        "HLA-DRB1*01"
      ]
    }
  ]
}